Better performance of CARs deprived of the PD-1 brake

Aizea Morales-Kastresana; Sara Labiano; José I Quetglas; Ignacio Melero

doi:10.1158/1078-0432.CCR-13-2157

Better performance of CARs deprived of the PD-1 brake

Clin Cancer Res. 2013 Oct 15;19(20):5546-8. doi: 10.1158/1078-0432.CCR-13-2157. Epub 2013 Sep 4.

Authors

Aizea Morales-Kastresana¹, Sara Labiano, José I Quetglas, Ignacio Melero

Affiliation

¹ Authors' Affiliation: Center for Applied Medical Research, CIMA and University Clinic, University of Navarra, Pamplona, Spain.

PMID: 24004672
DOI: 10.1158/1078-0432.CCR-13-2157

Abstract

Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Antibodies, Monoclonal / pharmacology*
Antineoplastic Agents / pharmacology*
Humans
Neoplasms / genetics*
Neoplasms / immunology*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
T-Lymphocyte Subsets / immunology*
T-Lymphocyte Subsets / metabolism*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Programmed Cell Death 1 Receptor